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Systematic Review and Meta-Analysis
Psychosocial factors associated with persistent
pain in people with HIV: a systematic review
with meta-analysis
Whitney Scotta,*, Chinar Arkutera, Kitty Kiosklia, Harriet Kempb, Lance M. McCrackena,c, Andrew S.C. Riceb,
Amanda C. de C. Williamsd
Abstract
Chronic pain remains a prevalent and disabling problem for people living with HIV in the current antiretroviral treatment era.
Psychosocial treatments may have promise for managing the impact of this pain. However, research is needed to identify
psychosocial processes to target through such treatments. The current systematic review and meta-analysis examined the
evidence for psychosocial factors associated with pain, disability, and quality of life in people living with HIV and persistent pain.
Observational and experimental studies reporting on the association between one or more psychosocial factors and one or more
pain-related variables in an adult sample of people living with HIV and pain were eligible. Two reviewers independently conducted
eligibility screening, data extraction, and quality assessment. Forty-six studies were included in the review and 37 of these provided
data for meta-analyses (12,493 participants). “Some” or “moderate” evidence supported an association between pain outcomes in
people with HIV and the following psychosocial factors: depression, psychological distress, posttraumatic stress, drug abuse, sleep
disturbance, reduced antiretroviral adherence, health care use, missed HIV clinic visits, unemployment, and protective
psychological factors. Surprisingly, few studies examined protective psychological factors or social processes, such as stigma.
Therewere few high-quality studies. These findings can inform future research and psychosocial treatment development in this area.
Greater theoretical and empirical focus is needed to examine the role of protective factors and social processes on pain outcomes in
this context. The review protocol was registered with PROSPERO (CRD42016036329).
Keywords: HIV, Pain, Systematic review, Psychosocial factors
1. Introduction
HIV remains a significant global health concern with 36.7 million
people living with HIV worldwide.130 The availability of combined
antiretroviral therapy (cART) has drastically improved life expec-
tancy.9,93,120 In well-resourced countries, and increasingly in less
well-resourced regions, the shift in HIV from a terminal illness to
a chronic condition has led to a focus on disease and symptom
management.59
Chronic pain is a common symptom in people with HIV. Data
from one systematic review indicate that 54% to 83% of people
with HIVmay experience clinically meaningful persistent pain, and
these estimates seem to be stable from the pre- to current-cART
era.80 Neuropathic pain is a frequent complication of HIV and/or
antiretroviral therapy.15 Approximately 42% to 66%of peoplewith
HIV have peripheral sensory neuropathy (HIV-SN), and around
54% to 78% of these experience neuropathic pain.84,88,129
Importantly, pain in people with HIV is associated with increased
disability and reduced quality of life.27
There are few pharmacological options for managing chronic
HIV-related pain. A systematic review of 14 randomized
controlled trials (RCTs) of pharmacotherapy for painful HIV-SN
found efficacy only for topical capsaicin, smoked cannabis, and
subcutaneous nerve growth factor.85 However, nerve growth
factor is not clinically available, capsaicin is not feasible in lower-
resourced settings, and a subsequent review of cannabis
showed no effect on neuropathic pain and concerns about
long-term side effects.32 Additional negative RCTs of pregabalin,
capsaicin, and amitriptyline have been published.17,24,103
In the wider literature, psychological approaches are common
in chronic pain management.34 Psychological treatments, in-
cluding cognitive–behavioural therapy (CBT), are associated with
improved functioning and mood for chronic pain that is primarily
musculoskeletal.124 However, research on psychological treat-
ments for pain in HIV is less well developed. Only 2 RCTs have
examined CBT for people with HIV and chronic pain, but
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interpretation of these trials is hampered by small samples118 and
high dropout rates.29 An observational study of CBT for HIV-
related pain showed similarly poor treatment completion.21,113
There is a clear need for improving psychological treatments for
people with HIV-related pain.
Improving psychological approaches for chronic pain in HIVwill
require consideration of the psychosocial complexities associ-
ated with HIV. For example, stigma, mental health problems, and
substance abuse may influence pain and treatment engagement
in people with HIV.36,69,71,111,123,132 However, research has not
systematically examined psychosocial factors associated with
pain in this context. The systematic review by Parker et al. (2014),
which estimated the prevalence of pain in HIV, described 5
studies reporting psychosocial factors. However, that review did
not specifically include assessment of psychosocial factors in the
eligibility criteria. Furthermore, 33 potentially eligible studies were
excluded due to low-quality ratings,80 which limits our un-
derstanding of the range of psychosocial factors examined in this
context. Therefore, we conducted a systematic review andmeta-
analyses to examine the associations between psychosocial
factors and persistent pain in HIV. Because the aims of the review
were exploratory, we did not formulate specific hypotheses about
the associations between these variables.
2. Methods
The review protocol was registered with PROSPERO (http://
www.crd.york.ac.uk/PROSPERO/display_record.php?ID5CRD
42016036329).
2.1. Inclusion and exclusion criteria
2.1.1. Inclusion
(1) People with HIV aged 18 years and older.
(2) The original protocol specified the study must have a “(sub)
sample with average pain duration of $3 months.” After
piloting this criterion, a large number of studies did not define
or report pain duration. We contacted authors to enquire
about pain chronicity; however, these data were generally not
available. Given the potentially high prevalence of chronic pain
in HIV,80 we decided to include studies with (sub)samples of
ambiguous pain duration, provided that “pain” vs “no pain”
subgroup analyses were reported in studies for which chronic
pain was not an eligibility criterion or which did not report pain
duration.
(3) Data on presence of pain, pain intensity, functioning, and/or
quality of life.
(4) Data on one or more psychosocial variable, representing any
potentially modifiable cognitive, affective, behavioural, or
interpersonal process. Adherence to antiretroviral therapy
and health care use variables represent modifiable behaviour
patterns. Therefore, we considered these as psychosocial
variables eligible for this review.
(5) Observational (cross-sectional, case-control, or prospective)
or experimental studies (RCTs) reporting between- or within-
groups associations between pain and psychosocial variables
in a (sub)sample with pain.
(6) Any language, from any region, from 1981 onwards (the date
that HIV was identified in the literature).
(7) Studies (published and unpublished) with an available full-text.
Where only abstracts or trial registration summaries were
available, the authors provided unpublished data for the
review. Unpublished studies are commonly included in
systematic reviews, given recognition of overestimation of
effects in published research.62 In addition, studies conducted
in lower-resourced countries where HIV is particularly
prevalent may not always proceed through to publication.
Therefore, the inclusion of unpublished studies and disserta-
tions may help overcome this disparity and allows us to
consider potential contextual differences.
2.1.2. Exclusion
(1) Studies only measuring associations between unchangeable
demographic factors (eg, age, ethnicity) and pain. While
piloting the eligibility criteria, we found a number of studies
reporting history of injecting drug use as participants’ HIV risk
factor. Given lack of further information about substance
abuse history or current abuse, we excluded studies for which
injecting drug use history was the only psychosocial factor.
Likewise, we excluded studies reporting only average units of
alcohol consumed, rather than alcohol abuse.
(2) Qualitative studies.
2.2. Search strategy
We searched the following databases during March 2016:
Medline, EMBASE, CINAHL, PsycINFO, Cochrane, and Web of
Science. We also searched ISRCTN, clinicaltrials.gov, and EU
Clinical Trials Register. Reference lists of eligible studies were
searched and key authors were contacted. We reran the search
in August 2017. The search included terms for the target
population (HIV or AIDS), outcome (chronic pain), and exposure
measurement (psychosocial factors). Relevant search terms
were identified from previous reviews on pain in HIV,80,124
psychosocial factors in HIV,99 and psychosocial factors in chronic
pain40 (Appendix A, available at http://links.lww.com/PAIN/
A643).
2.3. Data extraction
Two reviewers (W.S. and C.A.) independently screened titles/
abstracts and full-texts for eligibility. The following data were
extracted from eligible studies: year; design; country; sample
size; demographics (ie, age, sex, and race/ethnicity); clinical
factors (ie, HIV duration, use of ART, CD41 count and viral load,
and pain duration and type); assessment of pain and psychoso-
cial variables; and, statistical analyses. In cases where both
cross-sectional and prospective data reported the same (or an
overlapping) cohort and variables, the prospective analyses were
extracted. Data were extracted from all studies by W.S., and
independently by C.A. and K.K. who each extracted data from
approximately half of the studies. Disagreements regarding
eligibility and data extraction were discussed to reach consensus
and, where discrepancies remained, W.S. discussed these with
the wider team. The reviewers were not blinded to the authorship
of the studies reviewed.
2.4. Quality assessment
We assessed the methodological quality of studies using an
adapted version of quality assessment tools used in previous
systematic reviews of observational studies relevant to pain and
HIV.3,40,80 The quality assessment tool contained items
assessing: study purpose, recruitment, response rates,
sample description, assessment measurements, data analy-
sis, and confounding/matching (Appendix B, available at
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http://links.lww.com/PAIN/A643). Additional items assessed
features specific to prospective designs. Thus, quality scores
differed for cross-sectional and prospective studies. In some
cases, the overall study design did not correspond to the nature of
the data extracted for the purpose of this review. In addition, in
some cohorts, a cross-sectional design was used to examine one
psychosocial variable, whereas a prospective design was used to
examine another variable using the same sample. In all cases, the
quality assessmentwas applied to the design used for the nature of
the data extracted for a given psychosocial variable. Quality
assessment items were rated as “positive” (1), “negative” (0), or
“unclear” (?), and total scoreswere computed and classified as low
(,50%), medium (50%-80%), and high (.80%).3,40 W.S. com-
pleted quality assessment ratings for all studies, whereas C.A. and
K.K. each independently completed the quality assessment for
approximately half of the studies. The strength of evidence was
assessed according to the levels outlined by Arie¨ns et al.3 in
a systematic review of observational studies of psychosocial risk
factors for neck pain: (1) Strong: consistent results in multiple high-
quality prospective and/or case-control studies; (2) Moderate:
consistent results in multiple prospective and/or case-control
studies; (3) Some Evidence: findings in one prospective or case-
control study, or consistent findings in multiple cross-sectional
studies with at least one high-quality study; and (4) Inconclusive:
Inconsistent findings in multiple studies or consistent findings in
multiple low-quality cross-sectional studies.3
2.5. Data synthesis
Meta-analyses were conducted using Stata 15.0 where there
were at least 2 studies43 with the same design and effect
estimate of the association between the same pain (eg,
intensity) and psychosocial variables (eg, depression). We
took a broad approach to the meta-analyses,37,45 and
grouped psychosocial variables on the basis that they
reflected conceptually similar underlying constructs with
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA75) flow diagram.
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Table 1
Summary of the evidence for psychosocial variables.
Study quality Psychosocial assessment Study design/analyses Main summary
Depression
High: (n 5 2)79,84 BDI* (n 5 11); BSI (n 5 2) Prospective (HR) (n 5 2; Fig. S1,
http://links.lww.com/PAIN/A643)
Depression consistently positively associated
with pain presence, intensity, and interference,
and negatively with quality of life in prospective
and cross-sectional studies.
Medium: (n 5 19)
2,27,29†,31,48,50,60,61,67,88,89,91,
92,96,97,102,104,114,116,119
CDC (n 5 1); CES-D (n 5 6) Prospective (OR) (n 5 2; Fig. S2,
http://links.lww.com/PAIN/A643)
Evidence level: moderate
Low: (n 5 8)8,28,39,55,57,95,101,110 CIDI* (n 5 1); DAPOS (n 5 1) Cross-sectional (OR) (n 5 9, includes 1
cross-sectional case-control; Fig. 2)
DASS (n 5 1); GAIN (n 5 1) Cross-sectional (SMD) (n 5 13; Fig. 3/text)
HADS (n 5 1); HSC (n 5 1) Cross-sectional (correlation) (n5 8; Fig. S8,
http://links.lww.com/PAIN/A643/text)
PHQ (n 5 2); PRISM (n 5 1)
Nonvalidated (n 5 1)
Psychological distress
High: (n 5 1)84 BSI (n 5 2); CSQ (n 5 1) Prospective (OR) (n 5 1; in text) Distress consistently positively associated
with pain presence, intensity, and
interference in cross-sectional analyses, but
this was not consistent in the 2 prospective
studies.
Medium: (n 5 11)
2,29†,31,44,47,50,61,66,86,88,91,104
GAIN (n 5 1); HADS (n 5 1) Prospective (correlation) (n 5 1; in text) Evidence level: some
HSC*(n 5 1); INTRP (n 5 1) Cross-sectional (OR) (n 5 5; Fig. 4)
PASS (n 5 1); PCS* (n 5 4)
PHQ (n 5 1); POMS (n 5 1)
PRISM (n 5 1)
Low: (n 5 6)5,53,54,57,65,110 Clinician diagnosis‡ (n 5 1)
Medical file (ICD-9, n 5 1; unclear, n 5 2)
Cross-sectional (SMD) (n 5 8; Fig. 5/text)
Cross-sectional (correlation) (n5 5; Fig. S9,
http://links.lww.com/PAIN/A643)
Posttraumatic stress (PTSS)
High: (n 5 1)79 HTQ (n 5 1) Prospective (ANCOVA) (n 5 1; text) PTSS associated with poorer pain outcomes
in one prospective and one high-quality
cross-sectional study.
Medium: (n 5 2)31,107 PCL-C (n 5 1) Cross-sectional (SMD and correlation)
(n 5 1; text)
Evidence level: some
PRISM (n 5 1) Cross-sectional (OR) (n 5 1; text)
Drug abuse
Medium: (n 5 9)
47,52,60,67,76,92,104,114,119
CIDI (n 5 1); DIS-IV (n 5 1) Prospective (OR) (n 5 4; Fig. S10,
http://links.lww.com/PAIN/A643/text)
Pain and drug abuse consistently positively
associated in prospective and cross-
sectional studies.
Low: (n 5 5)39,53,54,81,110 GAIN (n 5 1); PRISM (n 5 1) Cross-sectional (OR) (n 5 8, includes 1
cross-sectional case-control; Fig. 6)
Evidence level: moderate
RBS (n 5 1) Cross-sectional (SMD) (n 5 1; text)
Medical file (ICD-9; n 5 1) Cross-sectional (correlation) (n 5 1; text)
Medical file (other; n 5 2)
Other self-report (n 5 6)
Alcohol abuse
Medium: (n 5 8)
27,52,60,76,77,115,117,119
CIDI (n 5 2); DIS-IV (n 5 1) Prospective (HR) (n 5 1; text) Lack of association between pain and
alcohol abuse in cross-sectional studies;
inconsistent findings in prospective studies.
Low: (n 5 3)6,39,56 DSM-IV (n 5 1); NIAAA (n 5 2) Prospective (OR) (n 5 3; Fig. S11, http://
links.lww.com/PAIN/A643/text)
Evidence level: inconclusive
PRISM (n 5 1); SCID (n 5 1) Cross-sectional (OR) (n 5 7) (Fig. S12,
http://links.lww.com/PAIN/A643)
Other self-report (n 5 2)
Unclear (n 5 1)
Sleep disturbance
High: (n 5 1)84 GSDS (n 5 1) Cross-sectional (SMD) (n 5 2; Fig. S13,
http://links.lww.com/PAIN/A643)
Sleep disturbance and pain positively
associated in 2/3 cross-sectional studies.
Medium: (n 5 2)2,94 ISI (n 5 1) Evidence level: some
PSQI (n 5 1) Cross-sectional (correlation) (n 5 1; text)
(continued on next page)
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Table 1 (continued)
Study quality Psychosocial assessment Study design/analyses Main summary
Antiretroviral nonadherence
Medium: (n 5 2)66,68 ACTG-AQ (n 5 5) Prospective (OR) (n 5 1; text) Pain associated with reduced antiretroviral
adherence in one prospective study and
majority of cross-sectional studies.
Evidence: some
Low: (n 5 5)8,46,57,72,110 Other self-report (n 5 2) Cross-sectional (OR) (n 5 4; Fig. S14/15,
http://links.lww.com/PAIN/A643)
Cross-sectional (correlation/SEM; n 5 2;
text)
Health care use
Medium: (n 5 4)47,61,68,119 Medical records (GP/HIV/urgent care visits)
(n 5 4)
Prospective (OR) (n 5 1; text) Pain associated with greater health care use
in one large prospective study and 2 large
cross-sectional studies. No association in 3
relatively small cross-sectional studies.
Low: (n 5 2)39,53 Self-report (mental health treatment) (n5 2) Cross-sectional (OR) (n 5 2; Fig. S16,
http://links.lww.com/PAIN/A643)
Evidence level: some
Cross-sectional (SMD) (n 5 3; Fig. S17,
http://links.lww.com/PAIN/A643/text)
Missed HIV clinic visits
Medium: (n 5 2)68,92 Medical records Prospective (OR) (n 5 2; Fig. S18, http://
links.lww.com/PAIN/A643)
Pain associated with greater missed HIV
clinic visits based on pooled effect of 2 large
prospective studies.
Evidence level: some
Unemployment
High: (n 5 1)79 WPAIQ (n 5 1) Cross-sectional (OR) (n 5 8, includes 1
cross-sectional case-control; Fig. S19,
http://links.lww.com/PAIN/A643)
Pain consistently associated with
unemployment (cross-sectional studies).
Medium: (n 5 7)2,27,61,92,114,119,121 Other self-report (n 5 7) Evidence level: some
Protective factors
High: (n 5 1)79 ACTG-AQ self-efficacy item (n 5 1) Prospective (correlation) (n 5 1) Resilience (1 case-control), acceptance (1
prospective), and self-efficacy (2 cross-
sectional, including 1 high quality)
associated with improved pain outcomes.
Optimism examined in only one low-quality
cross-sectional study.
Evidence level: some
Medium: (n 5 2)86,121 CPAQ (n 5 1) Cross-sectional (OR) (n 5 1)
Low: (n 5 2)8,101 Life orientation test (n 5 1) Cross-sectional (SMD/correlation) (n 5 3,
includes 1 cross-sectional case-control)
The resilience scale (n 5 1) All discussed in text
SE-6 (n 5 1)
Social factors
Medium: (n 5 3)73,74,91,122 HASI-P (n 5 1) (stigma) Prospective (correlation) (n 5 1) Too few studies, lack of high-quality studies,
and some inconsistencies for social
processes (eg, negative support/support
quality)
Low: (n 5 2)72,98 RSS (n 5 1) (stigma) Cross-sectional (OR) (n 5 1) Evidence level: inconclusive
SSQ-SF (n 5 1) (support quality/number) Cross-sectional (SMD/correlation) (n 5 3)
Self-report: Negative support/support
reciprocity/patient–provider engagement
(not validated; n 5 1)
All discussed in text
As justified in the Methods, we chose to focus on interpreting bivariate data. However, studies reporting a multivariate model between psychosocial and pain variables are bolded in column 1 for ease of reference. Additional
references relating to the same or overlapping studies reported in Table 1: 11, 12, 13, 22, 30, 70, 90, 105.
* Where different measures of the same variable were used for between-groups and within-group analyses in the same study, both measures are reported.
† Reference for multivariate analyses related to bivariate data reported in Ref. 29 is Ref. 38.
‡ Patient report of diagnosis of mental illness by a clinician.
ACTG-AQ, AIDS Clinical Trials Group Adherence Questionnaire; ANCOVA, analysis of covariance; BDI, Beck Depression Inventory; BSI, Brief Symptom Inventory; CDC, Centers for Disease Control; CES-D, Centre for
Epidemiological Studies Depression Scale; CIDI, Composite International Diagnostic Interview; CPAQ, Chronic Pain Acceptance Questionnaire; CSQ, Coping Strategies Questionnaire; DAPOS, Depression, Anxiety, and Positive
Outlook Scale; DASS, Depression Anxiety Stress Scales; DIS-IV, Diagnostic Interview Schedule for DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th Edition); GAIN, Global Appraisal of Individual Needs; GSDS;
General Sleep Disturbance Scale; HADS, Hospital Anxiety and Depression Scale; HASI-P, HIV/AIDS Stigma Scale—People Living with AIDS; HR, hazard ratio; HSC, Hopkins Symptoms Checklist; HTQ, Harvard Trauma
Questionnaire; ICD-9, International Classification of Disease mental illness/substance abuse codes extracted from medical file; INTRP, Inventory of Negative Thoughts in Response to Pain; ISI, Insomnia Severity Index; NIAAA,
National Institute on Alcoholism and Alcohol Abuse Guidelines; OR, odds ratio; PASS, Pain Anxiety Symptom Scale; PCL-C: PTSD Checklist-Civilian; PCS, Pain Catastrophizing Scale; PHQ, Patient Health Questionnaire
Depression/Anxiety Module; POMS, Profile of Mood States—Tension/Anxiety; PRISM, Psychiatric Research Interview for Substance and Mental Disorders; PSQI, Pittsburgh Sleep Quality Index; PTSS, posttraumatic stress
symptom; RBS, Risk Behaviour Survey; RSS, Reece Stigma Scale; SCID, Structured Clinical Interview for DSM-IV; SE-6, Self-Efficacy for Managing Chronic Disease—6 Item Scale; SEM, structural equation model; SMD,
standardized mean difference; SSQ-SF, Social Support Questionnaire—Short Form; WPAIQ, Work Productivity and Activity Impairment Questionnaire.
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overlapping measurement content. All analyses were con-
ducted using random effects, given likely heterogeneity.43
Between-study heterogeneity (I2 statistic) was interpreted as
low (,25%), medium (25%-50%), and high (.50%).124 For
between-groups comparisons of continuous data, mean
values, SDs, and sample sizes were extracted to compute
the pooled standardized mean difference (SMD). For between-
groups comparisons of dichotomous data, events data and
sample sizes were extracted. Where events data were not
reported, odds or hazard ratios, 95% confidence intervals
(95% CIs), and sample sizes were extracted. To aggregate
studies reporting a mixture of odds ratios (ORs) and events
Figure 2. Forest plot of cross-sectional odds ratios (ORs) for depression. Depression wasmore likely in participants with vs without pain, as reflected in the pooled
OR of.1. Gray boxes show weighting of individual studies; the red dotted line indicates the pooled effect around which effects from individual studies vary; the
blue diamond shows the 95% CI around the pooled effect. CI, confidence interval.
Figure 3. Forest plot of cross-sectional standardized mean differences (SMDs) for depression. Depression symptoms were more severe in participants with vs
without pain, as indicated by a positive pooled SMD. CI, confidence interval.
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data, ORs were first computed from studies reporting events
data and then pooled with ORs reported in other studies. Odds
ratios and hazard ratios were analysed separately. Where
applicable, correlation coefficients (Pearson r) were extracted
with sample sizes. We transformed r to Fisher z and computed
95% CIs of z to compute the pooled estimate.18,100
Data extracted were from bivariate analyses. Multivariate data
(eg, adjusted ORs) were only extracted where bivariate data were
not available. We focused on bivariate analyses because many
studies did not report multivariate analyses. Moreover, studies
that reportedmultivariatemodels varied substantially with respect
to control variables included and inconsistently used psychoso-
cial variables as independent or dependent variables. Taken
together, these differences limit meaningful interpretation of
multivariate analyses across studies.
Several studies presented data on more than 2 pain/no pain
groups, often with idiosyncratic group definitions, which limited
our ability to compare studies. Where studies reported 3 or more
groups, we collapsed these into 2 to represent groups with and
without pain (eg, frequent/moderate/severe vs infrequent/mild/
none), and computed effects between these. This approach
facilitated more direct comparison across studies and thus
enabled us to include a larger number of studies in the analyses.
For studies comparing participants on the presence of neurop-
athy, we prioritised extracting data from these comparisons in the
following order depending on the data reported: (1) painful vs
nonpainful neuropathy; (2) painful neuropathy vs no neuropathy;
and (3) neuropathy vs no neuropathy.Where there wasmore than
one measure of the same variable, we extracted data for the
measure with the widest usage or the longer measure to increase
reliability.124 Our protocol specified that funnel plots would be
inspected to assess for publication bias. However, due to the
relatively small number of studies in each meta-analysis and the
likelihood of high heterogeneity, inspection of funnels plots was
not appropriate109 and, therefore, was not undertaken.
We conducted sensitivity analyses to examine the influence of
the following study and patient characteristics on the findings:
certainty of pain chronicity, pain type, immune functioning and
viral suppression, ART treatment era, and health care system.
With the exception of the pain chronicity analysis, these sensitivity
analyses were prespecified. Given the large number of potential
analyses, we restricted sensitivity analyses to the between-
groups SMDs for depression because this was the analysis with
the largest number of studies.
3. Results
Forty-six studies were included in the review (13,480 participants)
and 37 of these provided data for meta-analyses (12,493
participants; Fig. 1). Most (83%) were conducted in the United
States, with 4 studies fromSouth Africa,79,88,121,122 and one each
from the United Kingdom,84 Thailand,89 Uganda,95 and Rus-
sia.114 Participants were primarily recruited from HIV clinics or
using multifaceted strategies that also included recruitment from
substance abuse clinics and community outreach. One study
recruited exclusively from a methadone clinic,8 whereas 2 others
recruited in high-poverty areas.39,110 The samples comprised
predominantly men in 41 studies, with the proportion of men in
these studies ranging from 51%50 to 100%.28,104 Five studies (4
from South Africa and 1 from the United States) recruited women
exclusively79,92 or predominantly (proportion of women ranging
from 72% to 88%).88,121,122 The mean age ranged from 30.1 (SD
5 5.2)114,115 to 51.0 (SD 5 9.3) years.119 HIV duration was not
consistently reported; however, of the studies providing data,
duration ranged from 2.09 (SD 5 1.22)102 to 16.95 years (SD 5
8.70).119 Eighteen studies (39%) reported on mixed HIV/AIDS
samples (reported proportion with AIDS ranged from 10% to
74%). Four studies included only participants with AIDS, one
study excluded patients with AIDS, whereas 23 studies did not
clearly report the proportion (if any) with AIDS. Supplemental
Table 1 shows further demographic characteristics of the study
samples (available at http://links.lww.com/PAIN/A643).
Table 1 provides a summary of study designs, quality, and
evidence level for each psychosocial factor. The studies showed
substantial variability in the measurement of pain and psychoso-
cial variables. Most studies (63%) were of medium quality. Fifteen
studies were of low quality, and only 2 were of high quality.79,84
The most common limitations included unclear reporting of
response rates, no a priori sample size justification, and poor
reporting of HIV and pain characteristics. There is no single
agreed upon strategy to best address low-quality studies within
meta-analyses, an issue which is compounded by the arbitrary
nature of study quality scoring and cutoff points.43 This can be
dealt with by only including high-quality studies, performing
sensitivity analyses, or including all studies irrespective of quality
and discussing risk of bias.43 Given that only 2 of 46 studies were
rated as high quality, ameta-analysis of these cannot be regarded
as reflecting most of the studies. Sensitivity analyses would
likewise not be meaningful. Including all studies is thus the most
justifiable approach for the current data. Although we have
chosen to focus on data from bivariate analyses for reasons
outlined in the Methods, studies that reported a multivariate
model of the association between psychosocial and pain
variables are shown in bold in Table 1 for ease of reference.
3.1. Depression
Depression was the most frequently assessed psychological
variable, investigated in 29 studies. Two prospective studies
reported hazard ratios for baseline depression predicting time to
onset of symptomatic neuropathy. The pooled hazard ratio was
significant and indicated that baseline depression was more
severe in participants who developed symptomatic neuropathy
at follow-up than those who did not: HR 5 1.04 (95% CI 1.02-
1.07), z 5 3.23, P 5 0.001 (supplemental Figure 1, available at
http://links.lww.com/PAIN/A643). Heterogeneity was 0.0%.
Two further prospective studies reported ORs. The pooled OR
was significant and indicted that higher baseline depression
symptoms were associated with greater likelihood of follow-up
pain: OR 5 2.26 (95% CI 1.47-3.47), z 5 3.72, P , 0.001
(supplemental Figure 2, available at http://links.lww.com/PAIN/
A643). Heterogeneity was medium (40.1%). Nine cross-
sectional studies provided events data or ORs. The pooled OR
was significant such that depression was more likely in
participants with vs without pain: OR 5 2.65 (95% CI 1.62-
4.34), z 5 3.90, P , 0.001 (Fig. 2). Heterogeneity was high
(83.0%). Twelve cross-sectional studies provided data to
compute SMDs (Fig. 3). The overall effect was significant and
showed moderately greater depression in participants with vs
without pain: SMD 5 0.68 (95% CI 0.42-0.93), z 5 5.22, P ,
0.001. Heterogeneity was high (I2 5 89.2%). Another cross-
sectional study that reported the median and interquartile range
found no difference in depression between groups with (n5 125)
and without pain (n 5 72).88
Six cross-sectional studies reported correlation coefficients
between depression and pain severity. The pooled correlation
was small, but significant: Fisher z5 0.26 (95%CI 0.18-0.33), z5
6.77, P , 0.001. Heterogeneity was 0.0%. One additional study
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found a nonsignificant correlation, although the coefficient was
not reported.27 Four cross-sectional studies reported correla-
tions between depression and pain interference/disability. The
pooled correlation was moderate: Fisher z5 0.48 (95% CI 0.41-
0.56), z 5 12.48, P , 0.001. Heterogeneity was 0.0%. Three
cross-sectional studies reported correlations between depres-
sion and quality of life. The pooled correlation was large and
significant: Fisher z520.52 (95% CI20.75 to20.30), z5 4.51,
P , 0.001. Heterogeneity was high at 73.3% (all correlation
analyses, supplemental Figure 8, available at http://links.lww.
com/PAIN/A643). One final cross-sectional study (n 5 120)
reported a moderate correlation between pain presence and
depression.55
3.2. Depression sensitivity analyses
We conducted sensitivity analyses on the SMDs for depression
between pain and no pain groups (supplemental Figures 3–7,
available at http://links.lww.com/PAIN/A643). We excluded data
from the Kirkland study here because the SMD from this study
was substantial and seemed to be driving heterogeneity in the
primary meta-analysis. Excluding the Kirkland data reduced
heterogeneity from I2 5 89.2% to 52.2%. Thus, 11 studies were
included in sensitivity analyses.
The pooled SMD for depression was medium for studies with
certain (0.61, 95%CI0.11-1.12, z52.39,P50.02; I2575.1%) and
uncertain pain chronicity (0.53, 95% CI 0.41-0.64, z 5 9.04,
Figure 4. Forest plot of cross-sectional events data for psychological distress. Distress was more likely in participants with vs without pain, as reflected in the
pooled odds ratio (OR) of .1. CI, confidence interval.
Figure 5. Forest plot of cross-sectional standardizedmean differences (SMDs) for psychological distress. Distress wasmore severe in participants with vs without
pain, as reflected by a positive pooled SMD. CI, confidence interval.
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P,0.001; I2534.5%). In the analysis by pain type, thepooledSMD
for depression wasmoderate in studies withmixed pain types (0.75,
95% CI 0.58-0.92, z5 8.51, P, 0.001; I25 31.7%) and for which
pain type was not reported (0.52, 95% CI 0.39-0.65; z5 7.91, P,
0.001; I25 0.0%). By contrast, studies with neuropathic pain (0.31,
95% CI 0.11-0.52; z 5 2.96, P 5 0.003; I2 5 0.0%) or headache
(0.38, 95% CI 0.06-0.70, z 5 2.34, P 5 0.02) showed small but
significant differences between groups on depression.
The pooled SMD for depression was moderate for studies in
which participants had less than adequate immune functioning and
viral suppression (0.56, 95%CI 0.42-0.70, z5 7.77,P, 0.001; I25
0.0%) and for studies in which these indicatorswere uncertain (0.53,
95%CI 0.33-0.73, z5 5.28,P, 0.001; I25 69.1%). There were no
studies with “adequate” functioning on these indices in this analysis.
Studies from the pre-cART (0.49, 95% CI 0.32-0.66, z5 5.75, P,
0.001; I2 5 0.0%), cART (0.73, 95% CI 0.37-1.10, z 5 3.91, P ,
0.001), and current-cART era (0.55, 95% CI 0.38-0.72, z5 6.21, P
, 0.001; I2 5 62.5%) all had moderate or near-moderate pooled
SMDs. Finally, pooled SMDs for depression were similar in studies
from the United States, which has amixed health care system (0.57,
95%CI 0.43-0.72, z5 7.58,P, 0.001; I25 55.7%), and one study
from the United Kingdom, which has universal health care (0.68,
95%CI 0.09-1.28; z52.25,P50.03). ThepooledSMDof 2 studies
conducted in lower- and middle-income countries was smaller, but
statistically significant (0.43, 95%CI 0.14-0.72, z5 2.90,P5 0.004;
I2 5 54.2%).
3.3. Psychological distress
Eighteen studies examined variables representing psychological
distress, including anxiety-related constructs and the presence of
“mental illness,” which generally described a combination of
anxiety and depression. Five cross-sectional studies provided
events data (Fig. 4). The pooled ORwas significant and indicated
that participants with pain were more likely to have psychological
distress than those without pain: OR5 2.56 (95% CI 1.67-3.90),
z 5 4.34, P , 0.001. Heterogeneity was high (I2 5 68.3%). One
prospective study (n5 127) found that baseline mental illness did
not predict presence of pain over follow-up.54 Seven cross-
sectional studies provided mean values and SDs (Fig. 5). The
pooled SMD showed a large and statistically significant difference
between groups such that distress was worse in participants with
vs without pain (SMD 5 0.85, 95% CI 0.35-1.35); z 5 3.33, P 5
0.001). Heterogeneity was very high (I2 5 95.4%). One further
study that reported the median and interquartile range found no
difference between groups.88
Four cross-sectional studies reported correlations between
distress and pain severity (supplemental Figure 9, available at
http://links.lww.com/PAIN/A643). The pooled correlation was
moderate: Fisher z 5 0.35 (95% CI 0.09-0.60), z 5 2.68, P 5
0.007. Heterogeneity was high (82.2%). Three cross-sectional
studies reported correlations between distress and pain
interference/disability. The pooled correlation was moderate:
Fisher z 5 0.59 (95% CI 0.24-0.93), z 5 3.34, P 5 0.001.
Heterogeneity was high (81.2%). One prospective study (n5 45-
62) found a nonsignificant correlation between change in distress
and pain severity after CBT, and a significant, moderate
correlation between change in distress and pain interference.44,86
Finally, one cross-sectional study reported a nonsignificant
correlation between pain intensity and distress (r not reported),
and a small negative correlation between distress and quality of
life.88
3.4. Posttraumatic stress
Three studies investigated posttraumatic stress. These studies
are reported separate from studies measuring psychological
distress, given the specificity of posttraumatic stress as a variable.
Different study designs and analyses precluded meta-analysis.
One prospective study (n5 143) found that posttraumatic stress
symptoms (PTSSs) were associated with significantly higher pain
severity and interference over time in a sample with HIV and
Figure 6. Forest plot of cross-sectional events data for drug abuse. Drug abuse wasmore likely in participants with vs without pain, as reflected in the pooled odds
ratio (OR) of .1. CI, confidence interval.
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persistent pain.107 One high-quality cross-sectional study found
that participants with pain (n5 170) had significantly higher PTSS
than those without pain (n 5 59).79 Within the pain group in this
study, there was a nonsignificant correlation between PTSSs and
pain severity, and small but significant correlations between
PTSSs and pain interference (positive correlation) and quality of
life (negative correlation).79 Posttraumatic stress disorder did not
differ between groups with (n 5 150) and without (n 5 128)
neuropathy in another cross-sectional study.31
3.5. Drug abuse
Fourteen studies examined drug abuse. We prioritised extracting
opioid abuse data when multiple drug abuse categories were
reported, given the relevance of opioid use in chronic pain. Two
prospective studies reported ORs for pain predicting heroin use
at the time of follow-up. The pooledOR indicated that participants
with pain at baseline were more likely at follow-up to be using
heroin: OR 5 1.70 (95% CI 1.22-2.38), z 5 3.13, P 5 0.002
(supplemental Figure 10, available at http://links.lww.com/PAIN/
A643). Heterogeneity was low (I2 5 14.0%). Conversely, another
prospective study (n 5 493) reported that baseline opioid use
disorder history predicted new onset of neuropathic pain, OR 5
2.87 (1.31-6.28), P , 0.01.60 One low-quality prospective study
(n 5 127) found that baseline drug abuse history did not predict
the presence of pain at follow-up, 0.55 (0.25-1.21).54 These 2
studies could not be combined due to different coding of the
dependent variable.
Eight cross-sectional studies reported events data (Fig. 6). The
pooled OR was significant such that participants with pain were
more likely to have comorbid drug abuse than those without pain:
OR5 1.59 (95%CI 1.12-2.26), z5 2.58,P5 0.01. Heterogeneity
was high (I25 69.8%), mainly attributable to one study that found
the opposite effect, such that participants with symptomatic
distal sensory polyneuropathy were less likely to have opioid use
disorder than those with asymptomatic distal sensory polyneur-
opathy.76 One low-quality cross-sectional study (n 5 503) found
that participants with “untreated” pain had greater dependence
symptoms than those with “treated” pain or without pain.110
Another low-quality cross-sectional study (n 5 73) found a small
positive correlation between “aberrant drug behaviours” and pain
interference, but not quality of life.81
3.6. Alcohol abuse
Eleven studies investigated alcohol abuse. Two prospective
studies reported ORs for baseline pain predicting subsequent
alcohol abuse. The pooled OR was not significant: OR 5 0.94
(95% CI 0.39-2.26), z5 0.13, P5 0.90 (supplemental Figure 11,
available at http://links.lww.com/PAIN/A643). Heterogeneity was
high (84.1%). Two additional prospective studies examined
baseline alcohol abuse as a predictor of developing pain/
neuropathy but could not be combined due to different analyses.
Both studies reported a nonsignificant association between these
variables.60,77 Seven cross-sectional studies provided events
data or ORs. The pooled ORwas not significant: OR5 1.22 (95%
CI 0.92-1.62), z 5 1.36, P 5 0.17 (supplemental Figure 12,
available at http://links.lww.com/PAIN/A643). Heterogeneity was
medium (I2 5 39.0%).
3.7. Sleep disturbance
Three studies investigated sleep disturbance. Two cross-
sectional studies reported mean values and SDs. The pooled
effect was significant and showed moderately greater sleep
problems in participants with vs without pain: SMD 5 0.66 (95%
CI 0.45-0.87), z 5 6.12, P , 0.001. Heterogeneity was 0.0%
(supplemental Figure 13, available at http://links.lww.com/PAIN/
A643). Another cross-sectional (n 5 45) study reported a signif-
icant correlation between pain severity and sleep disturbance,
and a nonsignificant correlation between sleep and functioning.94
3.8. Antiretroviral nonadherence
Seven studies investigated the association between pain and
suboptimal ART adherence. Data were analysed separately
according to whether the adherence variable was coded in the
direction of nonadherence or adherence. One prospective study
(n5 258) reported that severe pain at baseline predicted higher
odds (OR 5 1.37, 95% CI 1.02-1.85) of follow-up ART
nonadherence.46 One cross-sectional study provided events
data, whereas another provided an OR. The pooled OR was
significant and indicated that participants with pain were more
likely to report nonadherence: OR 5 1.40 (95% CI 1.07-1.82), z
5 2.50, P 5 0.01 (supplemental Figure 14, available at http://
links.lww.com/PAIN/A643). Heterogeneity was 0.00%. One
cross-sectional study (n 5 42) found significant positive
correlations between pain severity and adherence forgetfulness
and fears.57
Two cross-sectional studies reported data for the association
between pain and adherence (events data or OR). The pooled
OR was less than one, indicating the likelihood of adherence
was lower in participants with pain, but this was not statistically
significant: OR 5 0.32 (95% CI 0.08-1.32), z 5 1.57, P 5 0.12
(supplemental Figure 15, available at http://links.lww.com/
PAIN/A643). Heterogeneity was high (74.3%). Finally, one low-
quality cross-sectional study (n5 377) found that pain presence
was not associated with adherence in a structural equation
model.72
3.9. Health care use
Six studies examined health care use. One prospective study (n5
1521) found that baseline pain predicted significantly higher odds
(OR 5 1.6, 95% CI 1.2-2.0) of urgent care visits.68 Two cross-
sectional studies reported events data. The pooled OR was not
significant: OR 5 0.98 (95% CI 0.58-1.66, z 5 0.07, P 5 0.94)
(supplemental Figure 16, available at http://links.lww.com/PAIN/
A643). Heterogeneity was 0.0%. Two further cross-sectional
studies reported mean values and SDs. The pooled effect was
small but significant, such that participants with pain had greater
health care use than those without pain: SMD 5 0.36 (95% CI
0.21-0.51, z 5 4.66, P , 0.001). Heterogeneity was 0.0%
(supplemental Figure 17, available at http://links.lww.com/PAIN/
A643). One further cross-sectional study (n 5 1120) found that
participants with pain and daily opioid use had more clinic visits
than those with pain without daily opioid use and those without
pain (SD not reported).53
3.10. Missed HIV clinic visits
Two prospective studies reportedORs for baseline presence of pain
predicting missed HIV clinic visits over 1-year follow-up. The pooled
ORwas significant, such that those with pain at baseline had higher
odds of a missed HIV clinic visit: OR5 1.42 (95%CI 1.13-1.79), z5
2.98, P 5 0.003 (supplemental Figure 18, available at http://links.
lww.com/PAIN/A643). Heterogeneity was 0.0%.
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3.11. Unemployment
Seven cross-sectional studies provided events data or ORs for
the association between unemployment and pain. The pooled
OR was significant and indicated that participants with pain had
higher odds of being unemployed than those without pain: OR5
2.09 (95% CI 1.59-2.76, z 5 5.25, P , 0.001) (supplemental
Figure 19, available at http://links.lww.com/PAIN/A643). Hetero-
geneity wasmoderate (48.6%). One further cross-sectional study
(n 5 229) that did not have data available for meta-analysis
likewise found that participants with pain were significantly more
likely to be unemployed than those without pain.79
3.12. Protective factors
Five studies examined protective psychological factors. One
prospective study (n 5 62) found significant small and medium
correlations between change in self-reported pain acceptance
during CBT and posttreatment pain severity and interference,
respectively.86 One cross-sectional case-control study observed
lower resilience in participants with (n 5 99) vs without pain (n 5
98; medium effect); however, this study found nonsignificant
correlations between resilience and pain severity and interference
in the pain group.121
One high-quality cross-sectional study found that participants
with pain (n 5 170) reported lower disease management self-
efficacy than did those without pain (n 5 59) (small effect).79
Within the pain group in this study, there were nonsignificant
correlations between self-efficacy and pain severity and in-
terference, and a small positive correlation between self-efficacy
and quality of life.79 One low-quality cross-sectional study found
that those with greater adherence self-efficacy were less likely to
report pain (n 5 70).8 Finally, one low-quality cross-sectional
study found lower mean self-reported optimism in participants
with (n 5 50) vs without pain (n 5 46) (small effect).101
3.13. Social factors
Four studies investigated social factors. The BEACON study (n5
377) explored social processes across 3 papers, 2 of which
describe prospective data (medium quality), whereas the third
reported cross-sectional data (low quality). Baseline chronic pain
predicted “negative social support” (ie, overly intrusive or
insensitive responses from others and a lack of support) at 12
months, controlling for baseline social support.73 Another
prospective analysis showed that no chronic pain at baseline
predicted greater support reciprocity at follow-up.74 Chronic pain
was associated with significantly poorer ratings of patient–
provider engagement in cross-sectional analyses.72
Two studies examined self-reported stigma, but could not be
combined. One medium-quality cross-sectional study (n 5 50)
found a moderate positive correlation between stigma and pain
severity.122 One low-quality cross-sectional study (n 5 201)
found that participants with “pain disorder” reported higher
stigma scores than those without “pain disorder.”98 One
medium-quality cross-sectional study found no difference in
mean number or quality of self-reported social supports between
participants with (n 5 274) and without pain (n 5 164).91
4. Discussion
This review including over 13,000 participants found “some” or
“moderate” evidence supporting an association between pain
outcomes and depression, psychological distress, posttraumatic
stress, drug abuse, sleep disturbance, health care use, missed
HIV clinic visits, ART adherence, unemployment, and protective
psychological factors in people with HIV. Surprisingly few studies
have examined protective psychological factors or social pro-
cesses. There is a lack of high-quality research on psychosocial
factors related to chronic pain in people with HIV. These findings
can inform future research and treatment development in this
area.
The association between depression and poorer self-reported
pain outcomes in HIV is consistent with the wider pain
literature.4,64 Data from prospective studies suggest depression
is a risk factor for pain. However, caution is warranted in this
interpretation, given the observational nature of studies. There is
likely a bidirectional relationship, with shared neurobiological
pathways, cognitive appraisals, and behavioural disengagement
underpinning this association.4,7,14 Evidence supporting the
association between pain and sleep disturbance is consistent
with the wider literature that reports reciprocal associations
between pain, sleep, and depression.106
There was substantial variability in the assessment of “psycho-
logical distress,” which may have contributed to the statistical
heterogeneity observed. Although different measures were used to
assess variables such as pain catastrophizing, pain-related fear,
stress, and general anxiety, these measures overlap conceptually
and in item content. The consistency of results within the
psychological distress category suggests the findings are robust
across different assessment methods. Several studies assessed
“mental illness” based on a range of diagnoses in participants’
medical filewithout clear diagnostic criteria. Studies exploringmental
health diagnoses should use valid and reliable criteria and, ideally,
semi-structured clinician-administered interviews as the gold
standard.128 In light of high rates of posttraumatic stress disorder
(PTSD) inHIV,99 further research isparticularly needed tounderstand
the role of PTSD in pain in this context. Alternately, rather than
focusing on specificmental health diagnoses, research investigating
psychosocial processes that explain the impact of a range of
psychological difficulties may prove useful moving forward.42
Few studies investigated fear-avoidancemodel variables, such
as pain catastrophizing and pain-related fear, which have
dominated the musculoskeletal pain literature. Fear of movement
is strongly associated with musculoskeletal pain disability.20
However, neuropathic pain is often spontaneous and not clearly
provoked by movement, although it may inhibit movement.
Therefore, research is needed to determine the relevance of fear-
avoidance model constructs in neuropathic pain that is common
in HIV.
A bidirectional association between drug abuse and pain in HIV
is suggested by prospective data showing opioid abuse as both
predictor60 and outcome114 of pain. In a population where there
are concerns about analgesic prescribing,58 poorly managed
pain may contribute to increased abuse of nonprescribed
opioids, which may be exacerbated by depression.114 Alter-
nately, prolonged opioid abuse may disrupt descending pain
inhibition, exacerbating pain.49 Differing definitions of drug and
alcohol abuse across studies may account for variability in
effects. Future research on substance abuse in this context
should use validated assessments, either screening tools or
diagnostic interviews that capture key features of abuse, such as
continued use despite harm.1,41,128
Adherence to ART and retention in care are psychosocial
factors unique to the HIV context and are of vital importance,
given their associations with mortality, morbidity, and drug
resistance.112 The finding that pain was associated with reduced
ART adherence and missed HIV clinic visits highlights the
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necessity of adequate pain management in HIV. Understanding
the links between pain, ART adherence, and retention in care
likely requires consideration of other psychosocial factors, such
as substance abuse and depression, which may mediate or
moderate this association.68,92
Findings that pain was associated with greater unemployment
and health care use highlight the individual, societal, and
economic costs of pain in HIV. This is consistent with the broader
literature, although health care use is typically underassessed in
trials of psychotherapy for chronic pain.87 Studies assessing
health care use were restricted to the United States, whereas the
unemployment–pain link was consistent in studies from the
United States, Russia, and South Africa. The association
between pain and health care use differed across studies on
the basis of the type of health care assessed. Assessment of the
most frequently accessed services (eg, general practitioner visits),
rather than relatively infrequent events (eg, hospitalisations), may
increase the interpretability of future health care data.
Surprisingly, only 5 studies assessed protective psychological
factors. The lack of studies on protective factors mirrors historical
trends in the general pain literature, although there has been
greater focus on protective factors more recently. The focus on
“maladaptive” responses to pain is problematic because such
responses can be understood as a function of their short-term
utility.126 Moreover, abnormal conceptualizations often fail to
specify pathways through which recovery and successful
functioning occur when pain is present. The psychological
flexibility model, within which pain acceptance has been
conceptualised, might prove useful for future research.63
A recent proposal for updating the definition of pain highlights
the central role of social factors.127 However, our review identified
only 4 studies exploring interpersonal variables. The lack of
research on stigma in relation to pain is particularly surprising
because managing stigma is key to the success of the HIV/AIDS
response.108 Stigma has recently been highlighted as important
for the well-being of patients with chronic pain in general.23,125
Future research is needed to determine the function of stigma in
chronic pain in people with and without HIV.
The study samples included in our review variedwidely in terms
of the proportion of men and women, participant age, ethnicity,
and duration and severity of HIV. Our sensitivity analyses support
the potential applicability of findings across pain types, ART
treatment eras, and health care systems. Due to poor reporting of
viral loads and CD41 counts, our analysis stratifying by these
indicators is difficult to interpret. Caution is also warranted
regarding the cross-cultural applicability of the findings because
most studies were from the United States. One South African
study with a predominantly female sample found patients with
and without pain did not differ on depression or anxiety, likely due
to high scores across the sample.88 Socioeconomic factors, such
as poverty and gender, may thus alter the relationships between
pain, functioning, and mental health.88,121 Care is needed in
applying Western psychological concepts in non-Western
cultures.51,82,83 Research must also determine unique cultural
features that influence the experience and expression of pain
in HIV.
A guiding theoretical model is needed to integrate psychosocial
processes relevant to pain and HIV. Such a model should make
specific predictions about the relative contributions of cognitive,
affective, behavioural, and sociocultural processes in relation to
specific pain outcomes. This review identified a number of closely
related psychosocial constructs. Therefore, a theoretical model may
benefit from identifying a key set of nonoverlapping variables.63 This
may draw on prominent models within the field of pain, such as the
fear-avoidance19 and psychological flexibility models,63 and those
within the HIV literature that focus heavily on sociocultural
perspectives to understand the impact of processes, such as
stigma, on well-being.78
The current findings suggest the relevance of psychosocial
treatments to manage persistent pain in HIV. To the best of our
knowledge, only 3 small RCTs have evaluated CBT and
mindfulness-based treatment.29,35,118 Nonrandomized trials of
CBT113 and hypnosis25 have also been conducted. Further
evaluation of psychosocial treatments for HIV and chronic pain is
thus needed. The development of treatments that specifically
target psychosocial factors identified in this review with “some” or
“moderate” evidence may prove fruitful.
Several limitations warrant consideration.We used a comprehen-
sive search strategy that included efforts to identify gray literature to
limit publication bias; however, relevant studies may have been
missed, given the broad nature of the search. We used an adapted
quality assessment tool. Although we based this on previously
validated tools, the adaptations may have limited the reliability and
validity of our quality assessment. Assessment of pain was
inadequate in many studies. Future research should assess
information regarding pain duration, intensity, location, and type.
Studies investigating chronic pain should specify eligibility criteria in
line with recognized definitions: the presence of daily, clinically
meaningful pain intensity and functional interference for at least 3
months.10,26,131 Given the relevance of neuropathic pain in this
population, the use of well-validated screening tools of neuropathy
signs and symptoms is important.16,33,129
This review identified a large number of psychosocial factors.
As evidence on specific psychosocial factors develops in this
area, it may be useful for a future review to use a more targeted
approach to synthesize data on a smaller number of prespecified
variables. We focused on bivariate analyses and dichotomized
multiple between-groups analyses to facilitate comparison
across studies and minimise pairwise comparisons. However,
this may have limited an in-depth understanding of psychosocial
factors from multivariate models and more subtle subgroup
analyses. Future research examining the association between
psychosocial factors and pain outcomes in HIV should consider
controlling for such variables as age, sex/gender, race/ethnicity,
socioeconomic status, HIV duration, current and nadir CD41
count and current and peak viral load, current and past ART
regimens, and other medical comorbidities (eg, hepatitis C,
diabetes, and tuberculosis). Where multiple psychosocial varia-
bles are included, sufficient rationale for each variable should be
provided and care should be taken to minimize overlap in
assessment content between variables.
Despite these limitations, this is the first systematic review to
specifically explore psychosocial variables associated with
persistent pain in HIV. From this review, it is recommended that
researchers (1) focus greater attention on protective psycholog-
ical factors and social processes, such as stigma and processes
to undermine stigma; (2) use higher-quality assessment tools;
and (3) develop and test treatments to target key psychosocial
factors to improve pain outcomes in HIV. Improving quality of life
is a priority as people with HIV live longer. Adequate, whole-
person pain management is vital to achieve this goal.
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